John K. Simmons

Chemical and structural studies provide a mechanistic basis for recognition of the MYC G-quadruplex

David Calabrese, Xiang Chen, Elena C. Leon et al. · Nature Communications · 2018 · 166 citations · Full text

Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses

Taofeek K. Owonikoko, Huifeng Niu, Kristiaan Nackaerts et al. · Journal of Thoracic Oncology · 2019 · 141 citations · Full text

Small Molecule Microarrays Enable the Identification of a Selective, Quadruplex-Binding Inhibitor of MYC Expression

Kenneth M. Felsenstein, Lindsey B. Saunders, John K. Simmons et al. · ACS Chemical Biology · 2015 · 125 citations · Full text

Molecular Biology, Cancer Biology, Gene Expression Profiling +17

Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma

Matthew Labriola, Jason Zhu, Rajan T. Gupta et al. · Journal for ImmunoTherapy of Cancer · 2020 · 98 citations · Full text

Immunology, Immunoediting, Pathology +16

B Cell–Specific Deficiencies in mTOR Limit Humoral Immune Responses

Shuling Zhang, Margaret Pruitt, Dena Tran et al. · The Journal of Immunology · 2013 · 92 citations · Full text